Revenue Breakdown
Composition ()
No data
Revenue Streams
Xeris Biopharma Holdings Inc (XERS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product revenue -Recorlev , accounting for 49.7% of total sales, equivalent to $36.98M. Other significant revenue streams include Product revenue - Gvoke and Product revenue - Keveyis. Understanding this composition is critical for investors evaluating how XERS navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Xeris Biopharma Holdings Inc maintains a gross margin of 81.57%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 9.05%, while the net margin is 0.83%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively XERS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, XERS competes directly with industry leaders such as URGN and QURE. With a market capitalization of $1.02B, it holds a leading position in the sector. When comparing efficiency, XERS's gross margin of 81.57% stands against URGN's 88.07% and QURE's 89.25%. Such benchmarking helps identify whether Xeris Biopharma Holdings Inc is trading at a premium or discount relative to its financial performance.
